Heart Failure Clinical Trials in Houston, Texas

25 studies are recruiting for heart failure in Houston, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin

    Participants include men and women ≥ 40 years of age with T2DM, established CV disease, a history of HTN with an SBP of at least 130 mmHg at screening, who meet the predefined serum potassium level, and with at least one additional risk factor for HF. The study will include an optional pre-screenin…

    Stage
    Phase 3
    Ages
    40 and older
    Site
    Research Site, Houston, Texas
    Locations
    957 in total
    Run by
    AstraZeneca

    See if you can join NCT06677060 on ClinicalTrials.gov

  2. A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients

    Finerenone will be compared to placebo to determine efficacy and safety of treatment in patients hospitalized with acute decompensated heart failure (HF) and mildly reduced or preserved left ventricular ejection fraction.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Houston, TX Investigative Site 10085, Houston, Texas
    Locations
    356 in total
    Run by
    Colorado Prevention Center

    See if you can join NCT06008197 on ClinicalTrials.gov

  3. A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)

    Combination therapy of finerenone plus empagliflozin will be compared to usual care to determine the efficacy and safety of treatment in patients hospitalized with heart failure.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    CON-10085, Houston, TX, Houston, Texas
    Locations
    140 in total
    Run by
    Colorado Prevention Center

    See if you can join NCT06024746 on ClinicalTrials.gov

  4. Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure

    The goal of this study is to evaluate the safety and efficacy of the BrioVAD System by demonstrating non-inferiority to the HeartMate 3 Left Ventricular Assist System when used for the treatment of advanced, refractory, left ventricular heart failure.

    Stage
    Not phased
    Ages
    18 to 100
    Site
    Houston Methodist Hospital, Houston, Texas
    Locations
    47 in total
    Run by
    BrioHealth Solutions, Inc.

    See if you can join NCT06310031 on ClinicalTrials.gov

  5. A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart

    This study is open to adults with chronic heart failure (HF) who have a reduced left ventricular ejection fraction (LVEF) of less than 40%. People can join the study if they have been diagnosed with chronic HF at least 3 months before they start on the study. The purpose of this study is to find ou…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    The Methodist Hospital Research Institute, Houston, Texas
    Locations
    588 in total
    Run by
    Boehringer Ingelheim

    See if you can join NCT06935370 on ClinicalTrials.gov

  6. Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)

    This study aims to compare the efficacy of vericiguat versus placebo on change in n-terminal pro-brain natriuretic peptide (NTproBNP) from baseline to Week 16 of the Base Period. The primary hypothesis is that vericiguat is superior to placebo in reducing NT-proBNP at Week 16 of the Base Period.

    Stage
    Phase 2
    Ages
    0 to 17
    Site
    Texas Children's Hospital ( Site 0039), Houston, Texas
    Locations
    109 in total
    Run by
    Merck Sharp & Dohme LLC

    See if you can join NCT05714085 on ClinicalTrials.gov

  7. Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction

    The purpose of this study is to find out if the investigational drug called omecamtiv mecarbil can reduce the risk of the effects of heart failure, like hospitalization, transplantation, or death in patients with heart failure and severely reduced ejection fraction.

    Stage
    Phase 3
    Ages
    18 to 85
    Site
    CHI St. Luke's Health Baylor College of Medicine Medical Center, Houston, Texas
    Locations
    205 in total
    Run by
    Cytokinetics

    See if you can join NCT06736574 on ClinicalTrials.gov

  8. Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure

    Aortix is a circulatory support device for chronic heart failure patients on medical management who have been hospitalized for acute decompensated heart failure (ADHF) and have persistent congestion despite usual medical therapy. Eligible ADHF patients with diuretic resistance (irrespective of ejec…

    Stage
    Not phased
    Ages
    21 and older
    Site
    Texas Heart Institute, Houston, Texas
    Locations
    50 in total
    Run by
    Procyrion

    See if you can join NCT05677100 on ClinicalTrials.gov

  9. Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

    The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to evaluate the PK…

    Stage
    Not phased
    Ages
    0 to 20
    Site
    Baylor College of Medicine, Houston, Texas
    Locations
    52 in total
    Run by
    Duke University

    See if you can join NCT04278404 on ClinicalTrials.gov

  10. A Study of LY3971297 in Participants With Heart Failure

    The main purpose of this study is to assess how well LY3971297 is tolerated and what side effects may occur in participants with heart failure with preserved ejection fraction (HFpEF) and participants with heart failure with reduced ejection fraction (HFrEF). Blood tests will be performed to invest…

    Stage
    Phase 1
    Ages
    18 to 65
    Site
    Houston Methodist Hospital, Houston, Texas
    Locations
    12 in total
    Run by
    Eli Lilly and Company

    See if you can join NCT07547540 on ClinicalTrials.gov

  11. Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products

    The main purpose of the Product Performance Report (formerly referred to as System Longevity Study) is to evaluate long-term performance of Medtronic market-released cardiac rhythm products by analyzing product survival probabilities.

    Stage
    Not phased
    Ages
    Any age
    Site
    Research site, Houston, Texas
    Locations
    333 in total
    Run by
    Medtronic

    See if you can join NCT00271180 on ClinicalTrials.gov

  12. A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

    This study is being done to look at the safety and effect of NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced Ejection Fraction (HFmrEF) and excess body weight when compared to placebo. The purpose of this clinical study is to f…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    East Texas Cardiology PA, Houston, Texas
    Locations
    838 in total
    Run by
    Novo Nordisk A/S

    See if you can join NCT07567001 on ClinicalTrials.gov

  13. CSP #2025 - Geriatric OUt-of-hospital Randomized MEal Trial in Heart Failure: Veterans Affairs (GOURMET-VA)

    The purpose of this multi-center clinical trial is to study the efficacy and safety of providing nutritional support added to the study-defined standard of care which consists of standardized dietary education and a single dietary counseling session shortly after discharge, versus study-defined sta…

    Stage
    Not phased
    Ages
    60 and older
    Site
    Michael E. DeBakey VA Medical Center, Houston, TX, Houston, Texas
    Locations
    16 in total
    Run by
    VA Office of Research and Development

    See if you can join NCT05996328 on ClinicalTrials.gov

  14. Assessment of CCM in HF With Higher Ejection Fraction

    The AIM HIGHer Clinical Trial will evaluate the safety and efficacy of Cardiac Contractility Modulation (CCM) therapy in patients with heart failure with LVEF ≥40% and ≤70%.

    Stage
    Not phased
    Ages
    18 and older
    Site
    Baylor College of Medicine, Houston, Texas
    Locations
    105 in total
    Run by
    Impulse Dynamics

    See if you can join NCT05064709 on ClinicalTrials.gov

  15. A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy

    This study will look into how CDR132L (a potential new medicine) works on the structure and function of the heart in people living with heart failure. Participants will either get CDR132L or placebo (a medicine which has no effect on the body), which treatment the participants get is decided by cha…

    Stage
    Phase 2
    Ages
    40 to 84
    Site
    East Texas Cardiology PA, Houston, Texas
    Locations
    117 in total
    Run by
    Novo Nordisk A/S

    See if you can join NCT06979362 on ClinicalTrials.gov

  16. A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure Who Are Intolerant or Not Eligible for Treatment With Steroidal Mineralocorticoid Receptor Antagonists

    Finerenone will be compared to placebo to determine efficacy and safety of treatment in patients with heart failure and reduced ejection fraction (HFrEF) who are intolerant or ineligible to receive treatment with steroidal mineralocorticoid receptor antagonists (sMRA).

    Stage
    Phase 3
    Ages
    18 and older
    Site
    FIN-10085, Houston, TX, Houston, Texas
    Locations
    176 in total
    Run by
    Colorado Prevention Center

    See if you can join NCT06033950 on ClinicalTrials.gov

  17. 18F-mFBG Imaging for Myocardial Sympathetic Innervation

    This is a Phase 2 study evaluating the positron-emitting radiopharmaceutical 18F-mFBG as an imaging agent for quantification of myocardial sympathetic innervation. The study will examine a group of stable patients with heart failure (HF) from ischemic cardiomyopathy. All subjects will have left ven…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    UT Health Houston, Houston, Texas
    Run by
    Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)

    See if you can join NCT06965621 on ClinicalTrials.gov

  18. PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III

    This is a prospective, multi-center, open label, randomized control clinical trial evaluating the safety and efficacy of the Cordella™ Pulmonary Artery Sensor System in NYHA Class II-III Heart Failure Patients (PROACTIVE-HF-2 Trial). The study contains of 5 arms: NYHA II Cohort - To demonstrate saf…

    Stage
    Not phased
    Ages
    18 and older
    Site
    Baylor/Texas Heart, Houston, Texas
    Locations
    48 in total
    Run by
    Endotronix, Inc.

    See if you can join NCT05934487 on ClinicalTrials.gov

  19. Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure

    The purpose of TEAM-HF IDE clinical trial is to evaluate safety and effectiveness of the HeartMate 3 LVAS compared to guideline directed medical therapy (GDMT) in a population of ambulatory advanced heart failure patients who are not dependent on intravenous inotrope.

    Stage
    Not phased
    Ages
    18 and older
    Site
    CHI St. Luke's Health Baylor College of Medicine Medical Center, Houston, Texas
    Locations
    68 in total
    Run by
    Abbott Medical Devices

    See if you can join NCT06526195 on ClinicalTrials.gov

  20. Ultra-High Frequency - Electrocardiogram (UHF-ECG) for the Diagnosis of Ventricular Electrical Dyssynchrony (VED)

    The purpose of this study is to demonstrate the safety and effectiveness of the VDI UHF-ECG System in the diagnosis of ventricular dyssynchrony when compared to the 12-lead ECG in patients with bradycardia and heart failure indicated for pacemaker implantation.

    Stage
    Not phased
    Ages
    18 and older
    Site
    Baylor College of Medicine, Houston, Texas
    Locations
    12 in total
    Run by
    VDI Technologies

    See if you can join NCT06641362 on ClinicalTrials.gov

  21. The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMR

    The objective of this prospective, randomized, double- blinded (patient and assessors), sham-controlled clinical trial is to assess the safety and efficacy of the CMCS in treating heart failure with functional regurgitation (FMR).

    Stage
    Not phased
    Ages
    18 and older
    Site
    Houston Healthcare Medical Center, Houston, Texas
    Locations
    92 in total
    Run by
    Cardiac Dimensions, Inc.

    See if you can join NCT03142152 on ClinicalTrials.gov

  22. Left vs Left Randomized Clinical Trial

    The investigators aim to prospectively test the comparative effectiveness of His or Left bundle branch pacing in relation to patient centered outcomes (quality of life, physical activity, heart failure hospitalization, mortality) and comparative safety in relation to device-related complications an…

    Stage
    Not phased
    Ages
    18 and older
    Site
    Baylor College of Medicine, Houston, Texas
    Locations
    71 in total
    Run by
    Baylor College of Medicine

    See if you can join NCT05650658 on ClinicalTrials.gov

  23. Identification of Genomic Predictors of Adverse Events After Cardiac Surgery

    This study aims to identify genetic causes of adverse events after cardiac surgery, such as atrial fibrillation, myocardial infarction, renal dysfunction and heart failure. Patients undergoing heart surgery at Brigham and Women's Hospital and Texas Heart Institute are eligible to participate.

    Stage
    Not phased
    Ages
    20 to 90
    Site
    Department Texas Heart Institute at St. Luke's Episcopal Hospital, Houston, Texas
    Locations
    3 in total
    Run by
    Brigham and Women's Hospital

    See if you can join NCT01258231 on ClinicalTrials.gov

  24. BiVACOR® Total Artificial Heart Early Feasibility Study

    The purpose of this study is to assess the feasibility of using the BiVACOR Total Artificial Heart (TAH) System to support adult patients with severe biventricular heart failure, or univentricular heart failure in which left ventricular assist device (LVAD) support is not recommended, who require m…

    Stage
    Not phased
    Ages
    18 to 70
    Site
    Texas Heart Institute / Baylor St. Luke's Medical Center, Houston, Texas
    Locations
    4 in total
    Run by
    BiVACOR Inc.

    See if you can join NCT06174103 on ClinicalTrials.gov

  25. HF2 Registry - Hemodynamic Frontiers in Heart Failure Registry

    The purpose of the HF2 (Hemodynamic Frontiers in Heart Failure) registry is to collect relevant patient-level demographic, clinical, laboratory, and hemodynamic data from patients implanted with pulmonary artery pressure sensor at participating centers to advance scientific knowledge about ambulato…

    Stage
    Not phased
    Ages
    18 to 100
    Site
    Houston Methodist DeBakey Heart and Vascular Center, Houston, Texas
    Locations
    12 in total
    Run by
    University of Kansas Medical Center

    See if you can join NCT06425848 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.